Table 2 GSEA top 27 significantly enriched Pathways in Group 2 compared to Group 1 ordered by FDR q-value.
From: Systemic immune response alteration in patients with severe pressure ulcers
Pathway | FDR q-val | NES | n |
|---|---|---|---|
HAY_BONE_MARROW_FOLLICULAR_B_CELL | 0.000 | 2.47 | 141 |
GSE10325_CD4_TCELL_VS_BCELL_DN | 0.000 | 2.39 | 188 |
GSE10325_LUPUS_CD4_TCELL_VS_LUPUS_BCELL_DN | 0.000 | 2.35 | 191 |
GSE22886_NAIVE_BCELL_VS_NEUTROPHIL_DN | 0.000 | 2.32 | 198 |
REACTOME_CD22_MEDIATED_BCR_REGULATION | 0.000 | 2.20 | 47 |
GOCC_IMMUNOGLOBULIN_COMPLEX | 0.000 | 2.20 | 109 |
GSE22886_TCELL_VS_BCELL_NAIVE_DN | 5.88E− 04 | 2.12 | 186 |
GSE29618_BCELL_VS_PDC_UP | 5.46E− 04 | 2.12 | 194 |
AIZARANI_LIVER_C34_MHC_II_POS_B_CELLS | 6.83E− 04 | 2.10 | 131 |
REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS | 6.43E− 04 | 2.10 | 72 |
GSE3982_NEUTROPHIL_VS_EFF_MEMORY_CD4_TCELL_UP | 0.0012 | 2.08 | 193 |
GSE3982_MEMORY_CD4_TCELL_VS_BCELL_DN | 0.0018 | 2.07 | 192 |
GSE9988_ANTI_TREM1_VS_ANTI_TREM1_AND_LPS_MONOCYTE_DN | 0.0018 | 2.06 | 192 |
GSE25123_WT_VS_PPARG_KO_MACROPHAGE_UP | 0.0018 | 2.05 | 189 |
GSE36888_UNTREATED_VS_IL2_TREATED_TCELL_17H_DN | 0.0018 | 2.05 | 196 |
REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS | 0.0022 | 2.04 | 54 |
GSE29618_MONOCYTE_VS_MDC_UP | 0.0023 | 2.04 | 198 |
HAY_BONE_MARROW_NEUTROPHIL | 0.0025 | 2.03 | 440 |
GSE9988_ANTI_TREM1_VS_LPS_MONOCYTE_DN | 0.0029 | 2.02 | 196 |
GSE9988_ANTI_TREM1_VS_LOW_LPS_MONOCYTE_DN | 0.0033 | 2.015 | 196 |
GSE9988_ANTI_TREM1_AND_LPS_VS_VEHICLE_TREATED_MONOCYTES_UP | 0.0033 | 2.014 | 187 |
REACTOME_FCGR_ACTIVATION | 0.0037 | 2.009 | 56 |
GSE29618_BCELL_VS_MONOCYTE_UP | 0.0044 | 1.99 | 188 |
GSE22886_CD8_TCELL_VS_BCELL_NAIVE_DN | 0.0049 | 1.99 | 183 |
GSE9006_HEALTHY_VS_TYPE_1_DIABETES_PBMC_AT_DX_DN | 0.0057 | 1.98 | 190 |
GOCC_SPECIFIC_GRANULE | 0.0056 | 1.98 | 155 |
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT | 0.0057 | 1.98 | 61 |
